Comparison of Safety and Immunogenicity of a High Dose (5 x 10exp8 TCID50) and a Standard Dose (1 x 10exp8 TCID50) of IMVAMUNE in Healthy Vaccinia-Naive Individuals.

Trial Profile

Comparison of Safety and Immunogenicity of a High Dose (5 x 10exp8 TCID50) and a Standard Dose (1 x 10exp8 TCID50) of IMVAMUNE in Healthy Vaccinia-Naive Individuals.

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Dec 2012

At a glance

  • Drugs Smallpox vaccine (Primary)
  • Indications Smallpox
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 16 Feb 2012 Actual end date (Mar 2011) added as reported by ClinicalTrials.gov.
    • 16 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 30 Jan 2012 Actual patient number is 91 according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top